In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers Squibb and Otsuka Stabilize Their Bases

Executive Summary

The related deals between Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. announced in April appear to be a win for both sides. They extend and update a highly successful 10-year-old collaboration, essentially tweaking the original agreement's terms in consideration of each partner's current needs. At the same time, they recognize that the key product involved, the antipsychotic medication Abilify, is reaching maturity.

Related Content

With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Bristol-Myers's Grand Ambitions in Oncology
Can BMS Deliver on Innovation?
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009
Roche/Genentech: A Case Study For Future Hostile Offers
Takeda's Global Ambition
Takeda's Global Ambition
Takeda/ Millennium: The Price is Right
Takeda/ Millennium: The Price is Right


Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts